BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) was the target of a large growth in short interest in May. As of May 15th, there was short interest totalling 133,800 shares, a growth of 52.0% from the April 30th total of 88,000 shares. Approximately 2.4% of the company’s shares are short sold. Based on an average trading volume of 4,400,000 shares, the short-interest ratio is presently 0.0 days.

BioXcel Therapeutics Price Performance

Shares of NASDAQ BTAI opened at $1.18 on Monday. BioXcel Therapeutics has a 1-year low of $1.17 and a 1-year high of $29.28. The business has a fifty day moving average price of $1.67 and a 200 day moving average price of $3.82. The stock has a market capitalization of $7.15 million, a P/E ratio of -0.03 and a beta of 0.08.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Monday, May 12th. The company reported ($1.50) EPS for the quarter, topping analysts’ consensus estimates of ($2.72) by $1.22. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.35 million. As a group, equities research analysts anticipate that BioXcel Therapeutics will post -24.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. RODMAN&RENSHAW raised shares of BioXcel Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 19th. Rodman & Renshaw started coverage on BioXcel Therapeutics in a report on Wednesday, March 19th. They issued a “buy” rating and a $65.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Institutional Investors Weigh In On BioXcel Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in BioXcel Therapeutics during the 1st quarter worth about $50,000. Squarepoint Ops LLC grew its holdings in BioXcel Therapeutics by 203.9% during the fourth quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after acquiring an additional 48,336 shares during the period. Northern Trust Corp raised its position in BioXcel Therapeutics by 81.4% during the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock valued at $28,000 after acquiring an additional 33,161 shares in the last quarter. Murchinson Ltd. purchased a new position in BioXcel Therapeutics during the first quarter valued at approximately $276,000. Finally, Wells Fargo & Company MN lifted its holdings in BioXcel Therapeutics by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock valued at $74,000 after acquiring an additional 13,952 shares during the period. Institutional investors and hedge funds own 30.68% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.